132 related articles for article (PubMed ID: 25246247)
1. [Clinical significance of TET2 gene expression in 157 adult acute myeloid leukemia patients with normal cytogenetics].
Zhu Z; Chen J; Yu M; Chen F; Chen Z; Lou J; Tong H; Huang J; Qian W; Meng H; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):802-7. PubMed ID: 25246247
[TBL] [Abstract][Full Text] [Related]
2. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
3. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
4. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
Mohamed AM; Balsat M; Koering C; Maucort-Boulch D; Boissel N; Payen-Gay L; Cheok M; Mortada H; Auboeuf D; Pinatel C; El-Hamri M; Tigaud I; Hayette S; Dumontet C; Cros E; Flandrin-Gresta P; Nibourel O; Preudhomme C; Thomas X; Nicolini FE; Solly F; Guyotat D; Campos L; Michallet M; Ceraulo A; Mortreux F; Wattel E
Leuk Res; 2017 May; 56():21-28. PubMed ID: 28167452
[TBL] [Abstract][Full Text] [Related]
5. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
[TBL] [Abstract][Full Text] [Related]
7. Correlation of TET2 SNP rs2454206 with improved survival in children with acute myeloid leukemia featuring intermediate-risk cytogenetics.
Wang X; Chen X; Yang Z; Dou H; Lu L; Bi J; Zou L; Yu J; Bao L
Genes Chromosomes Cancer; 2018 Aug; 57(8):379-386. PubMed ID: 29664232
[TBL] [Abstract][Full Text] [Related]
8. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
9. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.
Chou WC; Chou SC; Liu CY; Chen CY; Hou HA; Kuo YY; Lee MC; Ko BS; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo YY; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
Blood; 2011 Oct; 118(14):3803-10. PubMed ID: 21828143
[TBL] [Abstract][Full Text] [Related]
10. Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S; Alpermann T; Grossmann V; Kowarsch A; Nadarajah N; Eder C; Dicker F; Fasan A; Haferlach C; Haferlach T; Kern W; Schnittger S; Kohlmann A
Leukemia; 2012 May; 26(5):934-42. PubMed ID: 22116554
[TBL] [Abstract][Full Text] [Related]
11. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
[TBL] [Abstract][Full Text] [Related]
12. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
[TBL] [Abstract][Full Text] [Related]
13. TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.
Damm F; Markus B; Thol F; Morgan M; Göhring G; Schlegelberger B; Krauter J; Heuser M; Bernard OA; Ganser A
Genes Chromosomes Cancer; 2014 Oct; 53(10):824-32. PubMed ID: 24898826
[TBL] [Abstract][Full Text] [Related]
14. The prognostic role of C-KIT, TET1 and TET2 gene expression in Acute Myeloid Leukemia.
Nabil R; Hassan NM; Abdellateif MS; Gawdat RM; Elshazly SS
Mol Biol Rep; 2023 Jan; 50(1):641-653. PubMed ID: 36371552
[TBL] [Abstract][Full Text] [Related]
15. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
[TBL] [Abstract][Full Text] [Related]
16. TET2 and MEG3 promoter methylation is associated with acute myeloid leukemia in a Hainan population.
Yao H; Duan M; Lin L; Wu C; Fu X; Wang H; Guo L; Chen W; Huang L; Liu D; Rao R; Wang S; Ding Y
Oncotarget; 2017 Mar; 8(11):18337-18347. PubMed ID: 28407691
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of the Effect of TET2 Mutation and SNP on Clinical Characteristics and Prognosis of AML Patients].
Li L; An LC; Chu XX; Liu XQ; Wang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):453-459. PubMed ID: 32319378
[TBL] [Abstract][Full Text] [Related]
18. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
19. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
20. Meningioma 1 (MN1) expression: refined risk stratification in acute myeloid leukemia with normal cytogenetics (CN-AML).
Aref S; Ibrahim L; Morkes H; Azmy E; Ebrahim M
Hematology; 2013 Sep; 18(5):277-83. PubMed ID: 23394438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
